相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents
David E. Kandzari et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
Pascal Vranckx et al.
LANCET (2018)
Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial
Thomas Pilgrim et al.
LANCET (2018)
Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial
Clemens von Birgelen et al.
LANCET (2018)
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial
Alexandra Lansky et al.
LANCET (2018)
Comparison of everolimus-eluting bioresorbable vascular scaffolds and metallic stents: three-year clinical outcomes from the ABSORB China randomised trial
Bo Xu et al.
EUROINTERVENTION (2018)
Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug- Eluting Stents
Georges El-Hayek et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2017)
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation
Masato Nakamura et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2017)
Coronary balloon angioplasty, stents, and scaffolds
Robert A. Byrne et al.
LANCET (2017)
Efficacy and Safety of a Biodegradable Polymer Cobalt-Chromium Sirolimus-Eluting Stent (EXCEL2) in Treating De Novo Coronary Artery Disease: A Pooled Analysis of the CREDIT II and CREDIT III Trials
Geng Wang et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2017)
Three-Year Clinical Outcomes of Everolimus-Eluting Stents From the Post-Marketing Surveillance Study of Cobalt-Chromium Everolimus-Eluting Stent (XIENCE V/PROMUS) in Japan
Jiro Aoki et al.
CIRCULATION JOURNAL (2016)
Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent Randomized Substudy of the I-LOVE-IT 2 Trial
Yaling Han et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2016)
Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds Evidence From a Network Meta-Analysis of 147 Trials
Si-Hyuck Kang et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2016)
First-in-Man Study Evaluating the Safety and Efficacy of a Second Generation Biodegradable Polymer Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Lesions: Clinical, Angiographic, and OCT Outcomes of CREDIT-1
Geng Wang et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2015)
Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease ABSORB China Trial
Runlin Gao et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Long-Term Efficacy and Safety of Biodegradable-Polymer Biolimus-Eluting Stents Main Results of the Basel Stent Kosten-Effektivitats Trial-PROspective Validation Examination II (BASKET-PROVE II), A Randomized, Controlled Noninferiority 2-Year Outcome Trial
Christoph Kaiser et al.
CIRCULATION (2015)
Three-Year Results Comparing Platinum-Chromium PROMUS Element and Cobalt-Chromium XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Narrowing (from the PLATINUM Trial)
Ian T. Meredith et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial
Pieter Cornelis Smits et al.
LANCET (2013)
Sustained clinical safety and efficacy of a biodegradable-polymer coated sirolimus-eluting stent in real-world practice: Three-year outcomes of the CREATE (multi-center registry of EXCEL biodegradable polymer drug eluting stents) study
Yaling Han et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2012)
Head-to-Head Comparison of the Neointimal Response Between Metallic and Bioresorbable Everolimus-Eluting Scaffolds Using Optical Coherence Tomography
Josep Gomez-Lara et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2011)
Attenuated mTOR Signaling and Enhanced Autophagy in Adipocytes from Obese Patients with Type 2 Diabetes
Anita Ost et al.
MOLECULAR MEDICINE (2010)
Clinical end points in coronary stent trials - A case for standardized definitions
Donald E. Cutlip et al.
CIRCULATION (2007)
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents
Adnan Kastrati et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Stent thrombosis in randomized clinical trials of drug-eluting stents
Laura Mauri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Pathology of drug-eluting stents in humans - Delayed healing and late thrombotic risk
Michael Joner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
分享论文
